InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: genisi post# 1561

Sunday, 05/13/2007 3:15:58 AM

Sunday, May 13, 2007 3:15:58 AM

Post# of 3562
Mylan beats Teva for Merck KGaA

Mylan Laboratories paid $6.7 billion for Merck KGaA’s generic business
Gil Shlomo 13 May 07 10:02
Mylan Laboratories Inc. (NYSE: MYL) has acquired the generic business of Germany’s Merck KGaA (XETRA: MRK) for $6.7 billion.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), the world’s largest generic pharmaceutical company, was reportedly Mylan’s chief rival in the tender. Mylan is Teva’s main competitor in the US generics market.

Published by Globes [online], Israel business news -
http://www.globes.co.il/serveen/globes/docview.asp?did=1000210935&fid=942
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TEVA News